• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol Compassionate Use of hzVSF-v13 in Two Patients With Severe COVID-19

tetano

Editor, Senior Moderator
J Med Virol


. 2020 May 26.
doi: 10.1002/jmv.26063. Online ahead of print.
Compassionate Use of hzVSF-v13 in Two Patients With Severe COVID-19


Chang Kyung Kang[SUP] 1 [/SUP], Pyoeng Gyun Choe[SUP] 1 [/SUP], Sungman Park[SUP] 2 [/SUP], Taek Soo Kim[SUP] 3 [/SUP], Moon-Woo Seong[SUP] 3 [/SUP], Nam-Joong Kim[SUP] 1 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP], Wan Beom Park[SUP] 1 [/SUP], Yoon-Won Kim[SUP] 2 [/SUP]



Affiliations

Abstract

We report the compassionate use of humanized Virus Suppressing Factor-variant 13 (hzVSF-v13) in two patients with severe coronavirus disease 2019 (COVID-19) pneumonia. Both patients, including an 81-year-old man who required extracorporeal membrane oxygenation, showed clinical improvement. These results warrant placebo-controlled trials to evaluate the hzVSF-v13 efficacy against COVID-19. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; SARS-CoV-2; antiviral agents; hzVSF-v13.
 
Back
Top Bottom